0.00Open16.65Pre Close0 Volume0 Open Interest70.00Strike Price0.00Turnover0.00%IV2.13%PremiumNov 22, 2024Expiry Date15.49Intrinsic Value100Multiplier-4DDays to Expiry1.16Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.27Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Viking Therapeutics Stock Discussion
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
lets gooooooo
No comment yet